Keytruda (pembrolizumab)

pCPA File Number: 21553
Negotiation Status:
Concluded with an LOI
Indication(s):
For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)
Sponsor/Manufacturer:
Merck Canada Inc.
CADTH Project Number:
PC0235-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: